Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurinia Pharmaceuticals Inc.
Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
Hancock Jaffe Changes Name To enVVeno, Drops Cardiac Device To Focus On Venous Disease
The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.
Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating
From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alberta Ltd.
- Isotechnika Pharma Inc.
- Thunderbolt Pharma, Inc.